Treatment of murine lupus with CTLA4Ig.
暂无分享,去创建一个
[1] Bucy Rp,et al. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. , 1994, Arthritis and rheumatism.
[2] P. Lane,et al. B cell function in mice transgenic for mCTLA4-H gamma 1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4+ T cells , 1994, The Journal of experimental medicine.
[3] B. Hausmann,et al. Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo , 1994, The Journal of experimental medicine.
[4] J. Gribben,et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.
[5] P. Linsley,et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. , 1993, Science.
[6] L. Lanier,et al. B70 antigen is a second ligand for CTLA-4 and CD28 , 1993, Nature.
[7] C Anasetti,et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 , 1993, The Journal of experimental medicine.
[8] P. Linsley,et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Miller,et al. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. , 1992, Journal of immunology.
[10] P. Linsley,et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. , 1992, Science.
[11] P. Linsley,et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.
[12] H. P. Fell,et al. Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. , 1992, The Journal of biological chemistry.
[13] J. Allison,et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.
[14] A. Steinberg,et al. NIH conference. Systemic lupus erythematosus. , 1991, Annals of internal medicine.
[15] P. Linsley,et al. CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.
[16] J. Gribben,et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[17] P. Linsley,et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.
[18] P. Rabinovitch,et al. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. , 1990, Blood.
[19] F. Denizot,et al. A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.
[20] W. Seaman,et al. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4 , 1985, The Journal of experimental medicine.
[21] S. Swain,et al. Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. , 1984, Journal of immunology.
[22] R. Schwartz,et al. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.
[23] A. Weiss,et al. The role of the T3/antigen receptor complex in T-cell activation. , 1986, Annual review of immunology.